Nav: Home

Study reveals disparity between fibroblasts of different pancreatic diseases

May 18, 2020

Fibroblasts present in different pancreatic diseases are genetically distinct and their functions are 'programmed' by the unique environment of each disease, according to new research from the University of Liverpool (UK).

As well as different genetic profiles, the team found to their surprise, that disease-specific fibroblasts retain their unique gene expression following isolation and culture. As fibroblasts are a key drug development target for these diseases, the findings have important implications for how research is conducted.

Fibroblasts are the most common cells within the body's connective tissues and play a critical role in wound healing. But they can also be recruited by cancer cells to help them grow, spread and evade the body's immune system.

Funded in part by the UK charity Pancreatic Cancer Research Fund, the Liverpool team is the first to isolate, characterise and compare the properties of fibroblasts found in pancreatic cancer, chronic pancreatitis and periampullary tumours (a rare cancer affecting the area between the bile duct, pancreas and small intestine).

Lead researcher Professor Eithne Costello said: "It's long been thought that fibroblasts from different pancreatic diseases were very alike and have similar functions. But we've been able to show for the first time that this is absolutely not the case. While fibroblasts from distinct diseases share many properties, each disease changes the fibroblast in a different way and it's clear that researchers using fibroblasts for disease-specific research should ensure they use appropriate ones for their work."

The study, published in the journal Cancer Research, found that less than one quarter of activated genes were shared between fibroblasts isolated from different disease groups, compared to fibroblasts found in normal tissue. When comparisons were restricted to disease-associated fibroblasts only, less than one per cent of differentially expressed genes were common across disease types.

Fibroblasts are particularly abundant in pancreatic cancer, secreting growth factors and other chemicals to promote the growth of a fibrous scar-like coating around the tumour - the stroma - which prevents drugs from reaching the cancer cells within. It is this key role in the microenvironment of pancreatic cancer tumours and their complex interaction with surrounding cells that makes fibroblasts an important focus of research for finding potential drug targets.

When the team analysed blood samples from 230 patients with different pancreatic diseases and healthy donors, they found that pancreatic cancer patients had much higher levels of a protein produced by fibroblasts in the samples, compared to patients with chronic pancreatitis.

The protein - known as TNC - is one of the main proteins produced by fibroblasts to aid the growth of the stroma in pancreatic cancer. But intriguingly, when the team knocked down this protein from fibroblasts, and assessed its effect on the migration of pancreatic cancer cells, the cancer cells began to migrate more.

"It suggests that TNC in fibroblasts is somehow inhibiting the migration of cancer cells which is something that has not been reported before and warrants further investigation. It also underlines just how complex the interaction between fibroblasts and pancreatic cancer cells is," said co-researcher Dr Lawrence Barrera.

However, while TNC's potential as a therapeutic target remains unclear, the research team believes that the distinct difference in the levels of TNC found in the blood of patients with pancreatic cancer and those with chronic pancreatitis may be a potential biomarker to distinguish between the two diseases - something that currently can only be determined clinically or by a tissue biopsy.

Pancreatic Cancer Research Fund

Related Cancer Cells Articles:

New way to target some rapidly dividing cancer cells, leaving healthy cells unharmed
Scientists at Johns Hopkins Medicine and the University of Oxford say they have found a new way to kill some multiplying human breast cancer cells by selectively attacking the core of their cell division machinery.
Breast cancer cells use message-carrying vesicles to send oncogenic stimuli to normal cells
According to a Wistar study, breast cancer cells starved for oxygen send out messages that induce oncogenic changes in surrounding normal epithelial cells.
Breast cancer cells turn killer immune cells into allies
Researchers at Johns Hopkins University School of Medicine have discovered that breast cancer cells can alter the function of immune cells known as Natural killer (NK) cells so that instead of killing the cancer cells, they facilitate their spread to other parts of the body.
Breast cancer cells can reprogram immune cells to assist in metastasis
Johns Hopkins Kimmel Cancer Center investigators report they have uncovered a new mechanism by which invasive breast cancer cells evade the immune system to metastasize, or spread, to other areas of the body.
Engineered immune cells recognize, attack human and mouse solid-tumor cancer cells
CAR-T therapy has been used successfully in patients with blood cancers such as lymphoma and leukemia.
New liver cancer research targets non-cancer cells to blunt tumor growth
'Senotherapy,' a treatment that uses small molecule drugs to target ''senescent'' cells, or those cells that no longer undergo cell division, blunts liver tumor progression in animal models according to new research from a team led by Celeste Simon, PhD, a professor of Cell and Developmental Biology in the Perelman School of Medicine at the University of Pennsylvania and scientific director of the Abramson Family Cancer Research Institute.
Drug that keeps surface receptors on cancer cells makes them more visible to immune cells
A drug that is already clinically available for the treatment of nausea and psychosis, called prochlorperazine (PCZ), inhibits the internalization of receptors on the surface of tumor cells, thereby increasing the ability of anticancer antibodies to bind to the receptors and mount more effective immune responses.
Engineered bone marrow cells slow growth of prostate and pancreatic cancer cells
In experiments with mice, researchers at the Johns Hopkins Kimmel Cancer Center say they have slowed the growth of transplanted human prostate and pancreatic cancer cells by introducing bone marrow cells with a specific gene deletion to induce a novel immune response.
First phase i clinical trial of CRISPR-edited cells for cancer shows cells safe and durable
Following the first US test of CRISPR gene editing in patients with advanced cancer, researchers report these patients experienced no negative side effects and that the engineered T cells persisted in their bodies -- for months.
Zika virus' key into brain cells ID'd, leveraged to block infection and kill cancer cells
Two different UC San Diego research teams identified the same molecule -- αvβ5 integrin -- as Zika virus' key to brain cell entry.
More Cancer Cells News and Cancer Cells Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Warped Reality
False information on the internet makes it harder and harder to know what's true, and the consequences have been devastating. This hour, TED speakers explore ideas around technology and deception. Guests include law professor Danielle Citron, journalist Andrew Marantz, and computer scientist Joy Buolamwini.
Now Playing: Science for the People

#576 Science Communication in Creative Places
When you think of science communication, you might think of TED talks or museum talks or video talks, or... people giving lectures. It's a lot of people talking. But there's more to sci comm than that. This week host Bethany Brookshire talks to three people who have looked at science communication in places you might not expect it. We'll speak with Mauna Dasari, a graduate student at Notre Dame, about making mammals into a March Madness match. We'll talk with Sarah Garner, director of the Pathologists Assistant Program at Tulane University School of Medicine, who takes pathology instruction out of...
Now Playing: Radiolab

What If?
There's plenty of speculation about what Donald Trump might do in the wake of the election. Would he dispute the results if he loses? Would he simply refuse to leave office, or even try to use the military to maintain control? Last summer, Rosa Brooks got together a team of experts and political operatives from both sides of the aisle to ask a slightly different question. Rather than arguing about whether he'd do those things, they dug into what exactly would happen if he did. Part war game part choose your own adventure, Rosa's Transition Integrity Project doesn't give us any predictions, and it isn't a referendum on Trump. Instead, it's a deeply illuminating stress test on our laws, our institutions, and on the commitment to democracy written into the constitution. This episode was reported by Bethel Habte, with help from Tracie Hunte, and produced by Bethel Habte. Jeremy Bloom provided original music. Support Radiolab by becoming a member today at     You can read The Transition Integrity Project's report here.